[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatitis-d\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatitis-d":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,68,89,125,150,170,190,209],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":4,"leadSponsor":39,"locationsCount":42},"100054882","evaluation-of-patients-with-liver-disease-100054882",false,"NCT00001971","Evaluation of Patients With Liver Disease","* INCLUSION CRITERIA:\n\nAffected Subjects\n\nIn order to be eligible to participate in this study, an affected participant must meet all of the following criteria:\n\n1. \\>=2 years of age.\n2. Meets one of the following:\n\n   1. Suspected or evidence of acute or chronic liver disease on evaluation by a referring licensed independent practitioner (LIP), OR\n   2. At risk for acute or chronic liver disease\n\nHealthy Volunteers\n\nIn order to be eligible to participate in this study, a healthy volunteer must meet all of the following criteria:\n\n1. \\>= 18 years of age.\n2. In good general health as evidenced by medical history\n\nEXCLUSION CRITERIA:\n\nAffected Participants\n\nAn affected participant who meets any of the following criteria will be excluded from participation in this study:\n\n1\\. History of significant medical illnesses that might interfere with prolonged follow up evaluation\n\nHealthy Volunteers\n\nA healthy volunteer who meets any of the following criteria will be excluded from participation in this study:\n\n1. Any chronic medical condition, including (but not limited to) heart, kidney, or lung diseases\n2. Taking any regular medications or supplements (with the exception of regular multivitamins and\u002For oral contraceptives)\n3. Average alcohol consumption \\> 1 drink\u002Fday in past 6 months, per self-report\n4. History of liver disease (with the exception of neonatal jaundice)\n5. History of severe illness, infection or major surgery in the past year\n6. History of cancer (with the exception of basal cell carcinoma resected \\> 1 year prior to enrollment)\n7. BMI \\\u003C 18 or BMI \\>25\n8. Hemoglobin \\\u003C 11 (women) or hemoglobin \\\u003C 12 (men)\n9. ALT \\>35 (men) or ALT \\>25 (women)\n10. Alkaline Phosphatase \\>= 150\n11. Bilirubin \\>2 g\u002FdL\n12. HIV positive, Anti-HCV positive, HBsAg positive or Anti-HBc positive\n13. Pregnancy\n14. Inability to provide informed consent",true,"ALL","2 Years","100 Years",{"count":20,"type":21},8050,"ESTIMATED","OBSERVATIONAL","The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver.\n\nPatients participating in the study will first undergo a routine check-up as an outpatient. They will be asked to provide blood and urine samples for laboratory testing and will undergo an ultrasound of the liver. Ultrasound examinations use sound waves to determine the size and texture of the liver. After the initial visit subjects will be requested to follow-up once a year at the outpatient department for a similar check-up.\n\nAdditional tests may be requested throughout the study to provide information for other research studies and individual consent will be requested. These tests may include liver biopsies, skin biopsies, and \u002F or specialized blood, plasma, and lymphocyte examinations.\n\nSubjects that qualify for medications presently being studied may be offered the opportunity to benefit from experimental therapy.",[25,26,27,28],"Hepatitis D","Hepatitis C","Hepatitis B","Liver Disease",[27,26,25,30,31,28],"Chronic Hepatitis","Natural History","RECRUITING","2026-06-27",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"1992-05-27",{"name":40,"class":41},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":15,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100630759","oral-periodontal-evaluation-and-assessment-of-oral-fluid-biomarkers-in-patients-with-hepatitis-bd-100630759","NCT07491848","Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D","Oral-Periodontal Evaluation and Assessment of Biomarkers in Oral Fluids in Patients With Hepatitis B+D Treated With Bulevirtide","Inclusion Criteria:\n\n* Adults (≥18 years old) capable of providing informed consent.\n* For Hepatitis B+D groups: confirmed hepatitis B and D co-infection.\n* Bulevirtide group: receiving bulevirtide therapy as prescribed.\n* No Bulevirtide group: not receiving bulevirtide.\n* For Healthy Control group: systemically healthy adults without hepatitis B or D infection.\n* Willingness to undergo oral-periodontal examination, saliva and gingival crevicular fluid collection, and oral cavity photography.\n\nExclusion Criteria:\n\n* Patients with other systemic diseases that could influence periodontal health (e.g., uncontrolled diabetes, autoimmune diseases).\n* Patients currently receiving other experimental therapies that may affect oral or systemic inflammation.\n* Pregnancy or lactation.\n* Inability or unwillingness to provide informed consent.\n* History of oral or periodontal surgery within the last 6 months that could affect measurements.","18 Years",{"count":52,"type":21},25,"Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.",[55,25,56],"HEPATITIS B CHRONIC","Periodontitis","2026-03-19",{"date":59,"type":36},"2026-03-25",{"date":61,"type":36},"2026-02-15",{"date":63,"type":21},"2027-02-15",{"name":65,"class":66},"Research Center of Periodontal-Systemic Interactions","OTHER",2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":42},"100554853","immunological-and-virological-characterization-of-patients-with-chronic-hbv-hdv-infection-outcomes-and-response-to-bulevirtide-treatment-100554853","NCT06504485","Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment","Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Association With Disease Outcomes and Response to Bulevirtide Treatment","MPR_BD","Inclusion Criteria:\n\n* 18 years of age or older\n* Ability to understand and sign the informed consent\n* Chronic HDV infection defined by positivity of HBsAg antigen (HBV) and HDV RNA (HBV-HDV co-infection) for at least 6 months at the time of enrollment.\n\nExclusion Criteria:\n\n* Co-infection with other viruses (HCV, HIV)\n* Treatment with immunosuppressive\u002Fimmunomodulatory drugs\n* Other congenital and\u002For acquired immunodeficiency conditions",{"count":77,"type":21},192,"Pharmacological, single-center, non-profit observational study.\n\nThe present study is part of a cooperation project between the SC Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milan, Italy), the University of Milan, the University of Parma and Rome Tor Vergata, funded under the call for Research Projects of Significant National Interest - 2022 PNRR Call (Prot. P2022WEXP2).\n\nHepatitis D virus (HDV) is a defective RNA virus, which requires the presence of hepatitis B virus (HBV) to infect liver cells and propagate. To date, the mechanisms underlying the accelerated disease progression in the natural history of Delta hepatitis are poorly understood, as is the course of the HDV-specific immune response (CD4 and CD8 T cells). As in chronic HBV and HCV infections, the outcome of chronic HDV infection appears to be dictated primarily by the host immune response, which represents a key determinant for virus control or persistence. For HBV\u002FHDV coinfection, the role of T cells has not been well defined, as suitable animal models are lacking and so far few HDV-specific T cell epitopes have been precisely mapped, mainly limited to HLA-B alleles.\n\nThe study is divided into two substudies (cross-sectional and longitudinal). The primary objective of the cross-sectional study is to calculate the prevalence of HDV-specific T responses in patients with chronic HBV-HDV infection naïve to treatment with Bulevirtide. The primary objective of the longitudinal study is the change in the prevalence of HDV-specific T responses in patients with chronic HBV-HDV infection during treatment with Bulevirtide compared to baseline (pre-treatment).",[25],"2026-01-13",{"date":82,"type":36},"2026-01-15",{"date":84,"type":36},"2024-09-01",{"date":86,"type":21},"2026-02-28",{"name":88,"class":66},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":109,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100595931","community-screening-and-management-of-hepatitis-b-c-and-delta-in-the-mongolian-population-living-in-france-100595931","NCT07038863","Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France","Community Screening for Hepatitis B, C and Delta in the Mongolian Population Living in France","Mondelta","Inclusion Criteria:\n\n* Mongolian people\n* Over 15 years of age\n* Living in France\n* Majors agree to participate or minors whose parental guardians agree to their child's participation in the study\n\nExclusion Criteria:\n\n* People already followed for viral hepatitis, treated or not treated\n* Persons deprived of their liberty by a judicial or administrative decision\n* Adults subject to a legal protection measure (guardianship, curators)\n* People participate in any interventional research except routine care research (old regulation) and category 2 research that does not interfere with the primary endpoint analysis","15 Years",{"count":99,"type":21},2000,"INTERVENTIONAL",[102],"NA","In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, specific therapies are available to reduce the morbidity and mortality of these patients. A study carried out in California in the Mongolian community found an HBV prevalence of 9.7% and positive HDV serology in 41% of these patients.\n\nThere is a large Mongolian community in France, estimated at between 5,000 and 6,000 patients. Although the majority of these patients are covered by French social security; however, access to care and screening for viral hepatitis often remain difficult and insufficient for migrant or vulnerable populations in France The aim of this study is to screen the Mongolian community in France for viral hepatitis, and then initiate a program of care and treatment.",[105,106,25,107,108],"HEPATITIS C (HCV)","Hepatitis B Virus (HBV)","Hepatocellular Carcinoma (HCC)","Liver Fibrosis",[110,111,112,113],"HBV","HCV","HDV","HCC","NOT_YET_RECRUITING","2025-06-18",{"date":117,"type":36},"2025-06-26",{"date":119,"type":21},"2025-09-01",{"date":121,"type":21},"2028-05-01",{"name":123,"class":66},"Hospices Civils de Lyon",11,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":134,"conditions":135,"keywords":136,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":42},"100511179","delta-describe-the-french-collaborative-project-100511179","NCT05936073","DELTA DESCRIBE: the French Collaborative Project","DELTADESCRIBE","Inclusion Criteria:\n\n* \\>18 years at the second step\n* HDV RNA positive patients identified at the second step\n* Patients non opposed to the collection of their data\n\nExclusion Criteria:\n\n* Opposition expressed by the patients for the collection of their data",{"count":133,"type":21},734,"Our global objective is to draw up a photograph of HDV patients over one year in metropolitan France and identify the barriers of screening and care. The investigator suspects a mismatch between HBV and HDV screening, the first step for specialized care pathway in metropolitan France.",[25],[137,138,139,140],"HBs Ag","Delta hepatitis","Screening","Reflex testing","2025-05-24",{"date":143,"type":36},"2025-05-28",{"date":145,"type":36},"2024-01-22",{"date":147,"type":21},"2025-06-22",{"name":149,"class":66},"University Hospital, Limoges",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":42},"100525480","effectiveness-and-safety-of-bulevirtide-blv-therapy-in-patients-with-chronic-hepatitis-delta-chd-in-italy-d-shield-100525480","NCT06122285","Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)","Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy: a Multicenter Prospective Real Life Data Study","D-SHIELD","Inclusion Criteria:\n\n* 18 years of age or older\n* Chronic hepatitis delta\n* Compensated cirrhosis HDV related\n* Patients who will start therapy with BLV 2 mg\u002Fday from May 2023\n\nExclusion Criteria:\n\n* HDV-related decompensated cirrhosis (CPT ≥7)",{"count":159,"type":21},100,"Multicenter pharmacological observational prospective, no-profit, study.\n\nThis study was designed to get a \"real-life\" snapshot across several Italian Hepatology centers. All HDV patients are followed up according to EASL 2017 guidelines. This allows uniformity on the indication for antiviral treatment and management of that antiviral therapy. No off-label medications are used. All data are retrievable from the patient's medical record. In addition, clinical and biochemical data from patients at month 0, 1, 2, 4, 6 and 12 of treatment, and otherwise within the study period, will be collected longitudinally.\n\nThe primary objective of the study is to describe the virological response to BLV in all patients starting BLV therapy for CHD, defined as a \\>2 Log decline in HDV-RNA or undetectable HDV-RNA (using the Robogene 2.0 quantitative kit, LLQ \\\u003C6 IU\u002Fml) at month 12 of therapy.\n\nHDV patients who will start therapy with BLV 2 mg\u002Fday from May 2023, according to AIFA guidelines, will be consecutively enrolled.",[25],"2025-01-08",{"date":164,"type":36},"2025-01-10",{"date":166,"type":36},"2023-05-01",{"date":168,"type":21},"2025-12-31",{"name":88,"class":66},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":42},"100546662","effectiveness-and-clinical-outcomes-of-long-term-bulevirtide-monotherapy-in-patients-with-hdv-related-compensated-cirrhosis-100546662","NCT06397859","Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis","Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis (SAVE-D Study)","SAVE-D","Inclusion Criteria:\n\n* Age≥18 years\n* HDV-related compensated cirrhosis defined by positivity of HDV RNA for at least 6 months and clinical or laboratory or histological diagnosis of cirrhosis\n* Started treatment with BLV monotherapy between September 1st 2019 and 2025\n\nExclusion Criteria:\n\n* Chronic hepatitis without any evidence of cirrhosis\n* Decompensated cirrhosis\n* PegIFN alpha therapy",{"count":179,"type":21},266,"Retrospective and prospective, pharmacological, multicentre, non-profit observational study.\n\nConsecutive patients with HDV-related compensated cirrhosis starting Bulevirtide 2 mg\u002Fday from September 2019 to December 2025 will be enrolled in the study.\n\nAim of this study is to investigate virological and clinical effectiveness of Bulevirtide 2 mg\u002Fday in patients with HDV-related compensated cirrhosis in the real-life setting.\n\nPrimary endpoint of the study is the rate of virological response, defined as at least 2 Log decline or undetectable HDV RNA compared to baseline, at week 96 of treatment.",[25],"2024-06-14",{"date":184,"type":36},"2024-06-17",{"date":186,"type":36},"2024-05-06",{"date":188,"type":21},"2026-08-31",{"name":88,"class":66},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":205,"leadSponsor":207,"locationsCount":42},"100508693","standardising-care-for-hepatitis-delta-in-the-netherlands-100508693","NCT05903742","Standardising Care for Hepatitis Delta in the Netherlands","DREAM-2","Inclusion Criteria:\n\n* Active hepatitis delta based on a positive anti-HDV and a positive HDV-RNA test\n* Patients must be ≥18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* None",{"count":198,"type":21},80,"Rationale: Hepatitis delta virus (HDV) is a defective RNA virus that requires presence of hepatitis B virus (HBV) to complete virion assembly and secretion. HBV-HDV coinfection (\"hepatitis delta\") has been associated with severe liver injury that may result in rapid progression to cirrhosis and hepatic decompensation, as well as a higher risk of liver cancer when compared to patients with HBV mono-infection. Given the low incidence of hepatitis D, experience in caring for individuals with hepatitis delta is limited and management practices vary.\n\nObjective: Generate prospective follow-up data to increase our understanding of this rare disease.\n\nStudy design: Prospective observational cohort study spanning 5 years, during which we will collect standard clinical data as well as blood samples and quality of life questionnaires.\n\nStudy population: hepatitis delta patients aged ≥18 years Intervention (if applicable): not applicable Main study parameters\u002Fendpoints: Incidence of liver related events (liver cancer, (decompensation of) cirrhosis, liver transplantation) during follow-up and changes in markers of viral replication, inflammatory activity and liver stiffness over time.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: The risks associated with participation can be considered negligible and the burden can be considered minimal. The only additional action that the participants must perform are the filling out of two annual quality of life questionnaires, which are considered non-invasive, and collection of 10 ml blood during regular blood sample collections",[25],"2024-04-02",{"date":203,"type":36},"2024-04-03",{"date":145,"type":36},{"date":206,"type":21},"2031-09-01",{"name":208,"class":66},"Erasmus Medical Center",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":42},"100473914","registry-based-study-in-patients-with-hepatitis-d-virus-hdv-infection-in-china-100473914","NCT05451082","Registry-based Study in Patients With Hepatitis D Virus (HDV) Infection in China","Inclusion Criteria:\n\n* Adults aged 18 or above, both sex;\n* Evidence of a positive test for HDV RNA can be provided on or before the enrollment date;\n* Able to sign written informed consent.",{"count":216,"type":21},1000,"This is a retrospective, prospective, noninterventive, multicenter registry study. Patients diagnosed with HDV infection (based on positive HDV RNA) were included in this study and were followed up for at least 5 years to evaluate their disease progression and clinical outcomes (including death, liver transplantation, hepatocellular carcinoma \\[hcc\\], liver decompensation, and cirrhosis) during the 5-year follow-up period. All patients were followed up at least once a year after they were included in the study.\n\nIt was in 2016 HDV infection first reported in China. Since January 1, 2016, all patients diagnosed with HDV infection can be enrolled in this study and evidence confirming the diagnosis (including but not limited to HDV RNA test reports and medical records, etc.) must be delivered. The main test results (including serum HDV RNA, ALT, and tests to determine the presence of liver cirrhosis, decompensation of liver function, and liver cancer such as B-ultrasound and FibroScan) of these patients each year from diagnosis to enrollment should be collected and filled in the case report form (CRF).\n\nFollow-up data of patients with serum anti-HDV positive and HDV RNA negative can be recorded and followed up on this platform, with informed consent of the patients is required. Patients whose serum HBV RNA turn positive during the follow-up period will be included in the follow-up cohort of the study.",[25],[220],"hepatitis D virus","2022-07-07",{"date":223,"type":36},"2022-07-11",{"date":225,"type":21},"2022-07",{"date":227,"type":21},"2028-12",{"name":229,"class":66},"Lai Wei"]